<DOC>
	<DOCNO>NCT00000799</DOCNO>
	<brief_summary>To evaluate short-term long-term safety efficacy intravenous cidofovir ( HPMPC ) treatment small peripheral cytomegalovirus ( CMV ) retinitis lesion . To provide data relative safety efficacy 2 dos HPMPC maintenance regimen .</brief_summary>
	<brief_title>HPMPC ( Cidofovir ) Peripheral CMV Retinitis Trial Protocol</brief_title>
	<detailed_description>In Stage 1 , 30 patient randomize either observation deferral treatment retinitis progress ( observation group ) , intravenous HPMPC high dose two consecutive weekly induction dos , follow low dose every week maintenance . In Stage 2 , 70 patient randomized observation HPMPC high dose two consecutive weekly induction dose follow either dose every week maintenance , total three treatment group . Concomitant saline hydration probenecid administer patient receive HPMPC .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Probenecid</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Oral trimethoprim/sulfamethoxazole . Aerosolized pentamidine . Dapsone . Fluconazole . Ketoconazole . Itraconazole . Rifabutin . Filgrastim ( GCSF ) . Antiretroviral agent . Patients must : AIDS CDC criterion . CMV retinitis determine SOCAcertified ophthalmologist , lesion size , location , severity specify Disease Status field . Prior Medication : Allowed : Prophylaxis antiCMV agent . Exclusion Criteria Concurrent Medication : Excluded : Ongoing therapy CMV disease ganciclovir , foscarnet , CMV hyperimmune immunoglobulin , investigational agent antiCMV activity . Therapy nephrotoxic drug , include amphotericin B , aminoglycoside antibiotic , vidarabine , intravenous pentamidine . Patients follow prior condition exclude : History renal disease renal dialysis . History clinically significant cardiac disease , include symptom ischemia , congestive heart failure , arrhythmia . History clinically significant probenecid allergy . Prior Medication : Excluded : Prior therapy CMV disease ganciclovir , foscarnet , CMV hyperimmune immunoglobulin , investigational agent antiCMV activity . Therapy nephrotoxic drug within past 7 day , include amphotericin B , aminoglycoside antibiotic , vidarabine , intravenous pentamidine . Drug alcohol abuse sufficient hinder compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>cidofovir</keyword>
</DOC>